CISPOLY

JHcispoly, as an innovative and technology-based IVD company whose mission is to dedicated to develop advanced and innovative biotechnology, accelerating innovation in women's health. JHcispoly is focused on improving women’s health and lives. Our using the technology of methylation and population-scale clinical studies to overcome early gynecologic cancer detection challenges. With our proprietary technology, JHcispoly is also developing solutions to help accelerate more gynecological diseases diagnoses, and post-diagnostic applications. Our focus is on delivering products that allow physicians to stratify risk, facilitate early detection and optimize treatment plans.Our CE-cleared products CisCer®,CisEndo® and CisOva® detect the cervical cancer, endometrial cancer, ovarian cancer in women. Founded in 2020，JHcispoly is headquartered inBeijing. It is supported by leading global investors and biotechnologytechnology companies. For more information, please visit cispoly.com.